BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32171112)

  • 1. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of
    Liu X; Zhang Y; Zhou CX
    Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wang CJ; Cui L; Ma HH; Wang D; Zhang L; Lian HY; Li WJ; Zhang Q; Wang TY; Li ZG; Zhang R
    Mol Cancer Ther; 2021 Jul; 20(7):1316-1323. PubMed ID: 33879554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
    Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.